Congratulations to Chintan Kapadia, who successfully defended his dissertation on March 21st! Kapadia’s research has focused on engineering PRINT nanoparticle-based delivery system for the intracellular delivery of tumor associated antigenic peptides and adjuvants to induce antigen specific potent cytotoxic T lymphocytes. His dissertation, “Engineering PRINT Nanoparticle Subunit Vaccine to Induce Antitumor Immune Response,” focused on the effect of particle size and chemical composition on the induction of antitumor immune response. His work addresses the need for more efficient delivery of antigenic peptides by tuning their intracellular release utilizing different chemical linkers.
His review article, “Nanoparticulate immunotherapy for cancer,” was recently published in the Journal of Controlled Release.
In his career, Kapadia aims to pursue research and leadership roles in the development of cancer immunotherapy in the pharmaceutical industry.